Subscribe to RSS
DOI: 10.1055/a-1925-7281
Validierungsstudie des MEP-Fragebogens zur erleichterten Erkennung von COPD-Exazerbationen
Validation study of MEP questionnaire for simplified detection of exacerbation of chronic obstructive pulmonary diseaseSupported by: Chiesi GmbH, DeutschlandTRIAL REGISTRATION: Registration number (trial ID): DRKS00015867, Trial registry: German Clinical Trials Register (https://drks-neu.uniklinik-freiburg.de/), Type of Study: Prospektive, epidemiologische, nicht-interventionelle Beobachtungsstudie
Zusammenfassung
Der Fragebogen „Monitoring of Exacerbation Probability“ (MEP) ist ein neuartiges, einfaches Instrument zur Unterstützung der Erkennung und semiquantitativen numerischen Dokumentation von Exazerbationen (ECOPD) in der täglichen Routine. In einer prospektiven, multizentrischen Studie an 810 Patienten in 21 Zentren wurde MEP unter realen Bedingungen bewertet und mit der Anwendung des EXACT-Pro-Fragebogen bei 3751 Visiten verglichen. Die in diese Studie eingeschlossene Population von COPD-Patienten ist demografisch und klinisch typisch für die gesamte COPD-Population. Da ein MEP-Wert von 1 oder mehr als positives Testergebnis definiert wurde, ergab sich eine Sensitivität von 91% und eine Spezifität von 66%. Außerdem korrelierten die MEP-Ergebnisse eindeutig mit den EXACT-Pro-Ergebnissen. Dies qualifiziert den MEP-Fragebogen als valides Instrument zur erleichterten Erkennung von ECOPD und zur longitudinalen Charakterisierung von COPD-Patienten.
Abstract
The Questionnaire “Monitoring of Exacerbation Probability” (MEP) provides a novel simple tool to assist detection and semiquantitative numerical documentation of exacerbation (ECOPD) in daily routine. In a prospective multi-center trial involving 3751 visits of 810 patients in 21 centers, MEP was evaluated and compared to the application of the EXACT-Pro questionnaire under real world conditions. The population of COPD patients included in this study is a typical COPD population demographically and clinically. Defining a MEP score of one or more as a positive test result, we found a sensitivity of 91% and a specificity of 66%. Additionally, MEP results correlated clearly with EXACT-Pro results. This qualifies the MEP questionnaire as a valid tool for the detection of ECOPD and longitudinal characterization of COPD patients.
Publication History
Received: 04 May 2022
Accepted after revision: 02 August 2022
Article published online:
18 October 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Pavord ID, Jones PW, Burgel P-R. et al. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2016; 11: 21-30 DOI: 10.2147/COPD.S85978. (PMID: 26937187)
- 2 Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev 2018; 27: 170103 DOI: 10.1183/16000617.0103-2017. (PMID: 29540496)
- 3 Suissa S, DellʼAniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957-963 DOI: 10.1136/thoraxjnl-2011-201518. (PMID: 22684094)
- 4 Donaldson GC, Seemungal TA, Bhowmik A. et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852 DOI: 10.1136/thorax.57.10.847. (PMID: 12324669)
- 5 Makris D, Moschandreas J, Damianaki A. et al. Exacerbations and lung function decline in COPD: New insights in current and ex-smokers. Respir Med 2007; 101: 1305-1312 DOI: 10.1016/j.rmed.2006.10.012. (PMID: 17112715)
- 6 Hurst JR, Vestbo J, Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138 DOI: 10.1056/NEJMoa0909883. (PMID: 20843247)
- 7 Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931 DOI: 10.1136/thx.2005.040527. (PMID: 16055622)
- 8 Çolak Y, Afzal S, Marott JL. et al. Prognosis of COPD depends on severity of exacerbation history: A population-based analysis. Respir Med 2019; 155: 141-147 DOI: 10.1016/j.rmed.2019.07.021. (PMID: 31362177)
- 9 GOLD. GOLD 2021 REPORT. https://goldcopd.org/
- 10 Hurst JR, Wedzicha JA. What is (and what is not) a COPD exacerbation: thoughts from the new GOLD guidelines. Thorax 2007; 62: 198-199 DOI: 10.1183/09031936.00009015. (PMID: 25829431)
- 11 Celli BR, Fabbri LM, Aaron SD. et al. An Updated Definition and Severity Classification of COPD Exacerbations: The Rome Proposal. Am J Respir Crit Care Med 2021; 204: 1251-1258 DOI: 10.1164/rccm.202108-1819PP. (PMID: 34570991)
- 12 Agusti A, Soler JJ, Molina J. et al. Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations?. COPD 2012; 9: 492-498 DOI: 10.3109/15412555.2012.692409. (PMID: 22958111)
- 13 Gottschalk F, Mueller S, Groth A. et al. Classification of Chronic Obstructive Pulmonary Disease (COPD) Severity According to the Global Initiative for Chronic Obstructive Lung Disease (Gold): Variations in the Defintion of Gold Groups and Their Impact on Stage Assignment. Value in Health 2017; 20: A772 DOI: 10.1016/j.jval.2017.08.2215.
- 14 Hering T, Andres J. The Patient Questionnaire “Monitoring of Exacerbation Probability (MEP)”. Pneumologie 2016; 70: 98-102 DOI: 10.1055/s-0041-110312.
- 15 BÄK, KBV, AWMF. Nationale Versorgungsleitlinie COPD Langfassung | Teilpublikation der Langfassung, 2. Auflage. Version 1. 2021. https://www.versorgungsleitlinien.de 2021 DOI: 10.6101/AZQ/000477
- 16 Celli BR, Vestbo J. The EXACT-Pro: measuring exacerbations of COPD. Am J Respir Crit Care Med 2011; 183: 287-288 DOI: 10.1164/rccm.201009-1401ED. (PMID: 21288860)
- 17 Muschelli J. ROC and AUC with a Binary Predictor: a Potentially Misleading Metric. Journal of Classification 2019; 37: 696-708 DOI: 10.1007/s00357-019-09345-1. (PMID: 33250548)
- 18 Fawcett T. An Introduction to ROC Analysis. Pattern Recognition Letters 2006; 27: 861-874
- 19 Akmatov M, Ermakova T, Holstiege J. et al. Überlappung von Asthma und COPD (ACOS) in der ambulanten Versorgung – Analyse anhand vertragsärztlicher Abrechnungsdaten. Zentralinstitut für die kassenärztliche Versorgung in Deutschland (Zi) 2020; DOI: 10.20364/VA-20.06.